26-27th September 2022, London
The Psychiatry Consortium sources and funds early-stage target validation studies via open funding calls to the global academic community. In addition to our open calls, we are now exploring a workshop-led approach to sourcing projects that align to key areas of common interest across the Psychiatry Consortium funding Partners;
•Psychiatric symptoms of dementia
In September 2022, we will hold a two-day, in-person workshop to bring together experts in genetics, neuroscience and drug discovery from academia, pharma/biotech, medical research charities, CROs and other key stakeholders.
The workshop aims to explore the evidence supporting a range of novel molecular therapeutic targets, identify the gaps in their validation and outline aspirational project development plans to fill those gaps.
During the workshop we will;
a) Critically evaluate the existing evidence for selected targets
b) Agree on the preclinical data of evidence required to validate promising targets, and outline potential experimental roadmaps to achieve them
c) Identify potential project partners and key opinion leaders to advise on project development and delivery
d) Strengthen relationships between academia and industry to support renewed efforts in collaborative psychiatric drug discovery
e) Provide opportunities for industry-academic networking and collaboration
If you would like to attend the workshop, please email [email protected] by 31st August 2022 with a short bio outlining your expertise in psychiatric drug development, disease expertise in one or more of the 4 key areas (mood, psychosis, cognition and psychiatric symptoms of dementia) and current research activity.
Senior PIs/Group leaders of academic and SME organisations are eligible to apply.